Online citations, reference lists, and bibliographies.
← Back to Search

Roles Of Signal Transducer Pathways In Investigation Of Biopsies From Patients With Bladder Tumors

A. Bayrak, S. Palanduz, E. Coskunpinar, O. Sanli, A. Armağan, S. Karakus, Ramazan Topaktaş, K. Cefle, Sukru Ozturk, A. Ucur
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background: The process of development of bladder cancer features alteration of normal biological conditions caused by changes in molecular pathways. Removing control over regulation of these pathways could lead to changes in signal transduction and abnormal regulation of genes. During tumor formation and progression, genes regulate critical cellular processes, involved in cell cycling, growth and death. Here we evaluated the expression and prognostic importance of FGFR1, HRAS, CCND1, CCND3, STAT3 and FAS genes. Methods: Tumor tissues of 44 patients diagnosed with bladder cancer were investigated for changes in expression levels of FGFR1, HRAS, CCND1, CCND3, FAS and STAT3 genes by the RT-PCR method. Signal transduction pathways and expression of individual genes related to these pathways were analyzed using the “One Sample Test”. Results: There were statistically significant changes in the expression levels of HRAS, CCND1, CCND3 and STAT3, but not FGFR1 and FAS genes. Examination of associations with age, gender, smoking, chemotherapy, tumor grade and tumor growth pattern using the “Independent Samples Test”, showed importance relations between the CCND1 gene and cigarette smoking and sex. Conclusion: Over-expression of HRAS, CCND1, CCND3 and STAT3 genes may play roles in bladder cancer development and progression, while cigarette smoking is significantly associated with CCND1 gene expression and consequently concluded to be contributing to the development of bladder cancer.
This paper references
10.1158/0008-5472.CAN-08-2816
Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.
D. Tomlinson (2009)
10.1002/ijc.10055
Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle‐associated proteins, cell proliferation and clinical outcome
A. Sgambato (2002)
10.1007/s10555-009-9196-5
Strategies for molecular expression profiling in bladder cancer
A. P. Mitra (2009)
10.1200/JCO.2008.18.5744
Generation of a concise gene panel for outcome prediction in urinary bladder cancer.
A. P. Mitra (2009)
10.1007/S00420-003-0457-2
Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer
K. Mundt (2003)
10.1177/107327480000700401
Molecular mechanisms and pathways in bladder cancer development and progression.
I. Jung (2000)
10.3322/caac.20077
Bladder Cancer in 2010: How Far have We Come?
B. Jacobs (2010)
10.22037/UJ.V5I4.31
Mutations of RAS gene family in specimens of bladder cancer.
N. Karimianpour (2008)
10.1016/j.juro.2009.01.011
Activation of RAS family genes in urothelial carcinoma.
I. Boulalas (2009)
10.1038/leu.2008.26
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. Steelman (2008)
10.1016/j.eururo.2009.09.013
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
M. Birkhahn (2010)
10.1002/ijc.21852
Understanding urothelial carcinoma through cancer pathways
W. Schulz (2006)
10.1093/toxsci/kfq028
Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.
R. Chen (2010)
10.1016/j.humpath.2010.07.007
Bladder cancer: translating molecular genetic insights into clinical practice.
L. Cheng (2011)
10.1111/j.1442-2042.2011.02809.x
Immunohistochemical biomarkers for bladder cancer prognosis
K. Matsushita (2011)
10.1016/J.HUMPATH.2006.05.017
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
S. Shariat (2006)
10.1146/annurev.pathol.4.110807.092230
Molecular pathogenesis and diagnostics of bladder cancer.
A. P. Mitra (2009)
2010).Bladder cancer in 2010: how far have we come
BL Jacobs (2010)
10.1038/sj.bjc.6990483
G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder
G. Niehans (1999)
10.1002/path.1952
Cyclin D3 expression in primary Ta/T1 bladder cancer
A. Lopez-Beltran (2006)



Semantic Scholar Logo Some data provided by SemanticScholar